US 10,376,530 B2
Pharmaceutical composition for preventing or treating gleevec-resistant leukemia containing ginsenoside F1 or ginsenoside Rg3 as an active ingredient
Sun Chang Kim, Daejeon (KR); and Hun Sik Kim, Seoul (KR)
Assigned to Intelligent Synthetic Biology Center, Daejeon (KR)
Appl. No. 15/511,637
Filed by INTELLIGENT SYNTHETIC BIOLOGY CENTER, Daejeon (KR)
PCT Filed May 4, 2016, PCT No. PCT/KR2016/004699
§ 371(c)(1), (2) Date Mar. 15, 2017,
PCT Pub. No. WO2016/178510, PCT Pub. Date Nov. 10, 2016.
Claims priority of application No. 10-2015-0063390 (KR), filed on May 6, 2015.
Prior Publication US 2018/0071327 A1, Mar. 15, 2018
Int. Cl. A61K 31/70 (2006.01); A61P 35/02 (2006.01); A61K 31/704 (2006.01); A61K 45/06 (2006.01); A61K 31/506 (2006.01); A23L 33/125 (2016.01); A61P 35/00 (2006.01)
CPC A61K 31/704 (2013.01) [A23L 33/125 (2016.08); A61K 31/506 (2013.01); A61K 31/70 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A23V 2002/00 (2013.01)] 2 Claims
 
1. A method for treating imatinib-resistant leukemia comprising administering a composition comprising ginsenoside F1 or a pharmaceutically acceptable salt thereof as the only active ingredient to a subject having or at risk of developing imatinib-resistant leukemia, wherein the leukemia is chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL), wherein ginsenoside F1 improves the cell-killing activity of natural killer cells.